VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure
- Written by PR Newswire
- VYNDAMAX has been listed on the Pharmaceutical Benefits Scheme (PBS) for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure.[1]
- ATTR-CM is a debilitating and often fatal condition that leads to heart failure.[2],[3]
- The availability of VYNDAMAX on...














